Press Releases

- STRIVE Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community -
- PTC's Disease Awareness Website - www.DuchenneAndYou.com now available in multiple languages -

-- Translarna™ net sales of $15.4M representing 150% year-over-year growth --
-- Full-year Translarna net sales on-track to meet guidance of $65M to $85M --
-- NHS England and NICE agreement completed allowing reimbursed access --
-- EMA review of European marketing authorization for Translarna continues --
-- FDA appeal process initiated in the U.S. --

SOUTH PLAINFIELD, N.J. , July 25, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced global regulatory updates on Translarna ™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) and nonsense mutation cystic fibrosis (nmCF).

SOUTH PLAINFIELD, N.J. , July 21, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Thursday, August 4, 2016

--Important decision allows reimbursed access to Translarna, the first approved therapy to treat the underlying cause of Duchenne muscular dystrophy--

SOUTH PLAINFIELD, N.J. , June 13, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently served as President of Merck's Europe / Canada region from 2009 to 2011 and as President

SOUTH PLAINFIELD, N.J. , June 10, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna™ (ataluren) for the treatment of nonsense mutation cystic fibrosis

STRIVE Awards Program Recognizes Excellence and Innovation in the Cystic Fibrosis Community

- Translarna&#8482 net sales of $18.9M representing 49% sequential growth -
- Full-year net sales on track to meet guidance of $65M to $85M -
- Proof of concept achieved in second SMA compound, RG7916 and clinical study in SMA patients planned for 2H of 2016 -

SOUTH PLAINFIELD, N.J. , April 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that Tuyen Ong , M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research .